EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

HER4 Affects Sensitivity to Tamoxifen and Abemaciclib in Luminal Breast Cancer Cells and Restricts Tumor Growth in MCF-7-Based Humanized Tumor Mice

Veruschka Albert, Christina Bruss, Deniz Tümen, Gerhard Piendl, Florian Weber iD, Edgar Dahl iD, Stephan Seitz, Olaf Ortmann, Anja K Wege iD, Gero Brockhoff iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25137475 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Veruschka Albert und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology and Obstetrics, University Medical Center Regensburg, 93935 Regensburg, Germany. Hauptthemen laut MEDLINE: Benzimidazoles, Tamoxifen, Breast Neoplasms, Aminopyridines. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wilhelm Sander-Stiftung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The impact of the HER4 receptor on the growth and treatment of estrogen receptor-positive breast cancer is widely uncertain. Using CRISPR/Cas9 technology, we generated stable HER4 knockout variants derived from the HER4-positive MCF-7, T-47D, and ZR-75-1 breast cancer cell lines. We investigated tumor cell proliferation as well as the cellular and molecular mechanisms of tamoxifen, abemaciclib, AMG232, and NRG1 treatments as a function of HER4 in vitro. HER4 differentially affects the cellular response to tamoxifen and abemaciclib treatment. Most conspicuous is the increased sensitivity of MCF-7 in vitro upon HER4 knockout and the inhibition of cell proliferation by NRG1. Additionally, we assessed tumor growth and immunological effects as responses to tamoxifen and abemaciclib therapy in humanized tumor mice (HTM) based on MCF-7 HER4-wildtype and the corresponding HER4-knockout cells. Without any treatment, the enhanced MCF-7 tumor growth in HTM upon HER4 knockout suggests a tumor-suppressive effect of HER4 under preclinical but human-like conditions. This phenomenon is associated with an increased HER2 expression in MCF-7 in vivo. Independent of HER4, abemaciclib and tamoxifen treatment considerably inhibited tumor growth in these mice. However, abemaciclib-treated hormone receptor-positive breast cancer patients with tumor-associated mdm2 gene copy gains or pronounced HER4 expression showed a reduced event-free survival. Evidently, the presence of HER4 affects the efficacy of tamoxifen and abemaciclib treatment in different estrogen receptor-positive breast cancer cells, even to different extents, and is associated with unfavorable outcomes in abemaciclib-treated patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzimidazolesTamoxifenBreast NeoplasmsAminopyridinesCell ProliferationReceptor, ErbB-4AnimalsHumansMiceFemaleMCF-7 CellsXenograft Model Antitumor AssaysCell Line, TumorDrug Resistance, Neoplasm

Stichwörter der Autor:innen

abemaciclibhormone receptor positive (HR+) breast cancerhuman epidermal growth factor receptor related (HER4)humanized tumor mice (HTM)tamoxifen

Substanzen

BenzimidazolesabemaciclibTamoxifenAminopyridinesReceptor, ErbB-4

Autor:innen und Institutionen

  • Department of Gynecology and Obstetrics, University Medical Center Regensburg, 93935 Regensburg, Germany.
  • Bavarian Cancer Research Center (BZKF), 93053 Regensburg, Germany.
  • Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany.
  • Institute of Pathology, University of Regensburg, 93093 Regensburg, Germany.
  • Institute of Pathology, Medical Faculty, RWTH Aachen University, 52074 Aachen, Germany.

ORCID-Profile: Florian Weber, Edgar Dahl, Anja K Wege, Gero Brockhoff

Förderung

  • Wilhelm Sander-Stiftung

Zitieren

APA

Albert, V., Bruss, C., Tümen, D., Piendl, G., Weber, F., Dahl, E., Seitz, S., Ortmann, O., Wege, A. K., & Brockhoff, G. (2024). HER4 Affects Sensitivity to Tamoxifen and Abemaciclib in Luminal Breast Cancer Cells and Restricts Tumor Growth in MCF-7-Based Humanized Tumor Mice. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25137475

Vancouver

Albert V, Bruss C, Tümen D, Piendl G, Weber F, Dahl E, et al. HER4 Affects Sensitivity to Tamoxifen and Abemaciclib in Luminal Breast Cancer Cells and Restricts Tumor Growth in MCF-7-Based Humanized Tumor Mice. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25137475

BibTeX
@article{Albert2024,
  author = {Albert, Veruschka and Bruss, Christina and Tümen, Deniz and Piendl, Gerhard and Weber, Florian and Dahl, Edgar and Seitz, Stephan and Ortmann, Olaf and Wege, Anja K and Brockhoff, Gero},
  title = {HER4 Affects Sensitivity to Tamoxifen and Abemaciclib in Luminal Breast Cancer Cells and Restricts Tumor Growth in MCF-7-Based Humanized Tumor Mice},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25137475}
}
Kostenlos starten →